-DOCSTART- -X- O
The -X- _ O
recent -X- _ O
2014â€“2016 -X- _ B-Patient
West -X- _ I-Patient
African -X- _ I-Patient
Ebola -X- _ I-Patient
virus -X- _ I-Patient
epidemic -X- _ I-Patient
underscores -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
novel -X- _ O
anti-Ebola -X- _ O
therapeutics -X- _ O
, -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
high -X- _ O
mortality -X- _ O
rates -X- _ O
of -X- _ O
Ebola -X- _ O
virus -X- _ O
infections -X- _ O
and -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
FDA-approved -X- _ O
vaccine -X- _ O
or -X- _ O
therapy -X- _ O
that -X- _ O
is -X- _ O
available -X- _ O
for -X- _ O
the -X- _ O
prevention -X- _ O
and -X- _ O
treatment. -X- _ O
Traditional -X- _ B-Intervention
Chinese -X- _ I-Intervention
medicines -X- _ I-Intervention
( -X- _ I-Intervention
TCMs -X- _ I-Intervention
) -X- _ I-Intervention
represent -X- _ O
a -X- _ O
huge -X- _ O
reservoir -X- _ O
of -X- _ O
bioactive -X- _ O
chemicals -X- _ O
and -X- _ O
many -X- _ O
TCMs -X- _ O
have -X- _ O
been -X- _ O
shown -X- _ O
to -X- _ O
have -X- _ O
antiviral -X- _ O
activities. -X- _ O
373 -X- _ O
extracts -X- _ O
from -X- _ O
128 -X- _ O
TCMs -X- _ O
were -X- _ O
evaluated -X- _ O
using -X- _ O
a -X- _ O
high -X- _ O
throughput -X- _ O
assay -X- _ O
to -X- _ O
screen -X- _ O
for -X- _ O
inhibitors -X- _ O
of -X- _ O
Ebola -X- _ B-Outcome
virus -X- _ I-Outcome
cell -X- _ I-Outcome
entry. -X- _ I-Outcome
Extract -X- _ O
of -X- _ O
Rhodiola -X- _ B-Intervention
rosea -X- _ I-Intervention
displayed -X- _ O
specific -X- _ O
and -X- _ O
potent -X- _ O
inhibition -X- _ O
against -X- _ O
cell -X- _ O
entry -X- _ O
of -X- _ O
both -X- _ O
Ebola -X- _ B-Outcome
virus -X- _ I-Outcome
and -X- _ I-Outcome
Marburg -X- _ I-Outcome
virus. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
, -X- _ O
twenty -X- _ O
commercial -X- _ O
compounds -X- _ O
that -X- _ O
were -X- _ O
isolated -X- _ O
from -X- _ O
Rhodiola -X- _ B-Intervention
rosea -X- _ I-Intervention
were -X- _ O
evaluated -X- _ O
using -X- _ O
the -X- _ O
pseudotyped -X- _ O
Ebola -X- _ O
virus -X- _ O
entry -X- _ O
assay -X- _ O
, -X- _ O
and -X- _ O
it -X- _ O
was -X- _ O
found -X- _ O
that -X- _ O
ellagic -X- _ O
acid -X- _ O
and -X- _ O
gallic -X- _ O
acid -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
two -X- _ O
structurally -X- _ O
related -X- _ O
compounds -X- _ O
, -X- _ O
are -X- _ O
the -X- _ O
most -X- _ O
effective -X- _ O
ones. -X- _ O
The -X- _ O
activity -X- _ O
of -X- _ O
the -X- _ O
extract -X- _ O
and -X- _ O
the -X- _ O
two -X- _ O
pure -X- _ O
compounds -X- _ O
were -X- _ O
validated -X- _ O
using -X- _ O
infectious -X- _ O
Ebola -X- _ O
virus. -X- _ O
The -X- _ O
time-of-addition -X- _ O
experiments -X- _ O
suggest -X- _ O
that -X- _ O
, -X- _ O
mechanistically -X- _ O
, -X- _ O
the -X- _ O
Rhodiola -X- _ B-Intervention
rosea -X- _ I-Intervention
extract -X- _ O
and -X- _ O
the -X- _ O
effective -X- _ O
compounds -X- _ O
act -X- _ O
at -X- _ O
an -X- _ O
early -X- _ O
step -X- _ O
in -X- _ O
the -X- _ O
infection -X- _ O
cycle -X- _ O
following -X- _ O
initial -X- _ O
cell -X- _ O
attachment -X- _ O
, -X- _ O
but -X- _ O
prior -X- _ O
to -X- _ O
viral -X- _ O
/ -X- _ O
cell -X- _ O
membrane -X- _ O
fusion. -X- _ O
Our -X- _ O
findings -X- _ O
provide -X- _ O
evidence -X- _ O
that -X- _ O
Rhodiola -X- _ B-Intervention
rosea -X- _ I-Intervention
has -X- _ O
potent -X- _ O
anti-filovirus -X- _ O
properties -X- _ O
that -X- _ O
may -X- _ O
be -X- _ O
developed -X- _ O
as -X- _ O
a -X- _ O
novel -X- _ O
anti-Ebola -X- _ O
treatment -X- _ O
. -X- _ O

